We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+12.89%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$992M
AUM Growth
+$216M
Cap. Flow
+$197M
Cap. Flow %
19.86%
Top 10 Hldgs %
62.98%
Holding
46
New
6
Increased
7
Reduced
8
Closed
2

Top Buys

Rank Stock Value
1
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$113M
2
SVA
Sinovac Biotech, Ltd
SVA
+$42.6M
3
AMRS
Amyris Inc.
AMRS
+$20.2M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$16.3M
5
ACER
Acer Therapeutics Inc
ACER
+$15.2M

Top Sells

Rank Stock Value
1
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$17.4M
2
RGNX icon
Regenxbio
RGNX
+$5.91M
3
SBBP
Strongbridge Biopharma plc.
SBBP
+$5.12M
4
CDXS icon
Codexis
CDXS
+$4.93M
5
QTTB icon
Q32 Bio
QTTB
+$4.72M

Sector Composition

Rank Sector Weight
1 Healthcare 95.48%
2 Materials 4.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.4B
$154M 15.48%
2,166,832
– –
CRNX icon
2
Crinetics Pharmaceuticals
CRNX
$8.88B
$109M 10.95%
+3,792,169
New +$113M
BHVN
3
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$77M 7.76%
2,049,545
– –
CDXS icon
4
Codexis
CDXS
$135M
$47.2M 4.75%
2,749,343
-305,482
-10% -$4.93M
SVA
5
DELISTED
Sinovac Biotech, Ltd
SVA
$45M 4.53%
+5,900,000
New +$42.6M
ARWR icon
6
Arrowhead Research
ARWR
$11.9B
$44.6M 4.5%
2,328,475
+428,475
+23% +$7.03M
AMRS
7
DELISTED
Amyris Inc.
AMRS
$44.3M 4.46%
5,575,118
+2,748,407
+97% +$20.2M
VYNE icon
8
VYNE Therapeutics
VYNE
$19.1M
$39.5M 3.98%
1,114
– –
KDMN
9
DELISTED
Kadmon Holdings, Inc.
KDMN
$34.9M 3.52%
10,454,545
– –
TCDA
10
DELISTED
Tricida, Inc. Common Stock
TCDA
$30.3M 3.05%
991,711
– –
KALV
11
DELISTED
KalVista Pharmaceuticals
KALV
$30.1M 3.03%
1,359,149
+1,058,824
+353% +$14.3M
QTTB icon
12
Q32 Bio
QTTB
$461M
$26.5M 2.67%
64,430
-13,889
-18% -$4.72M
LITS
13
Lite Strategy Inc
LITS
$33.4M
$24.9M 2.51%
288,905
-41,128
-12% -$3.37M
APLS
14
DELISTED
Apellis Pharmaceuticals
APLS
$24.1M 2.43%
1,354,554
-101,945
-7% -$1.88M
ACRS icon
15
Aclaris Therapeutics
ACRS
$743M
$23.9M 2.41%
1,647,214
– –
EIGR
16
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$21.5M 2.17%
59,709
– –
VRNA
17
DELISTED
Verona Pharma
VRNA
$18.7M 1.88%
1,492,951
– –
XENE icon
18
Xenon Pharmaceuticals
XENE
$6.28B
$18.6M 1.87%
+1,405,476
New +$16.3M
NBRV
19
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$17.9M 1.8%
26,477
+10,180
+62% +$7.22M
ACER
20
DELISTED
Acer Therapeutics Inc
ACER
$17.4M 1.76%
+565,579
New +$15.2M
OBSV
21
DELISTED
ObsEva SA Ordinary Shares
OBSV
$16.9M 1.7%
937,147
+12,147
+1% +$179K
RNAC icon
22
Cartesian Therapeutics
RNAC
$225M
$11.8M 1.19%
25,375
-645
-2% -$259K
GLMD icon
23
Galmed Pharmaceuticals
GLMD
$4.02M
$11.6M 1.17%
4,731
+327
+7% +$765K
KALA icon
24
KALA BIO
KALA
$12.3M
$10.3M 1.04%
418
– –
CBAY
25
DELISTED
Cymabay Therapeutics
CBAY
$10M 1.01%
906,000
– –
1
2

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
RCYC
Richard C. Young & Co Newport, Rhode Island $1.21B AUM 38.41% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return

Vivo Capital's Q3 2018 Portfolio in Review

As of Q3 2018, Vivo Capital held 46 positions worth $992M, up 28% from $776M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Vivo Capital deployed $197M of net new capital in Q3 2018, opening 6 new positions and adding to 7 existing holdings. Its largest new stake was Crinetics Pharmaceuticals: 3,792,169 shares worth $109M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 98% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was Strongbridge Biopharma plc., an estimated $5.12M trimmed.

  • Vivo Capital's largest Q3 2018 buy was Crinetics Pharmaceuticals: 3,792,169 shares worth $109M.
  • Vivo Capital added most to Amyris Inc. in Q3 2018, an estimated $20.2M increase.
  • Vivo Capital's biggest Q3 2018 reduction was Strongbridge Biopharma plc., cutting an estimated $5.12M.
  • Vivo Capital fully exited Madrigal Pharmaceuticals in Q3 2018, selling an estimated $17.4M.
  • Vivo Capital's ten largest holdings make up 63% of its $992M portfolio in Q3 2018.
  • Vivo Capital opened 6 new positions and closed 2 in Q3 2018.
  • Vivo Capital's portfolio value rose 28% quarter-over-quarter to $992M.

Based on Vivo Capital's 13F filing for Q3 2018, filed 13 Nov 2018.